Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Feb;41(2):292–297. doi: 10.1128/aac.41.2.292

Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.

G V Doern 1, A B Brueggemann 1, G Pierce 1, H P Holley Jr 1, A Rauch 1
PMCID: PMC163704  PMID: 9021182

Abstract

A total of 1,537 clinical isolates of Haemophilus influenzae were recovered in 30 U.S. medical center laboratories between 1 November 1994 and 30 April 1995 and were characterized in a central laboratory with respect to serotype and beta-lactamase production and the in vitro activities of 15 oral antimicrobial agents. Overall, 36.4% of the isolates were found to produce beta-lactamase. The rank order of activity of six cephalosporins on the basis of MICs was cefixime > cefpodoxime > cefuroxime > loracarbef > or = cefaclor > cefprozil. On the basis of current National Committee for Clinical Laboratory Standards (NCCLS) breakpoints ages of isolates found to be resistant or intermediate to these agents were as follows: 0.1, 0.3, 6.4, 16.3, 18.3, and 29.8, respectively (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. M7-A4, 1995). Azithromycin was, on a weight basis, the most potent of the macrolides tested in this study, followed by erythromycin and then clarithromycin. Azithromycin was typically fourfold more active than erythromycin, which was, in turn, slightly more active than clarithromycin. However, when compared on the basis of the frequency of resistance determined by using current NCCLS breakpoints, there was essentially no difference between azithromycin and clarithromycin, i.e., 0.5 and 1.9%, respectively (P = 0.086). Interpretive breakpoints for erythromycin MIC tests versus H. influenzae have not been developed. Resistance to other non- beta-lactam agents was variable, as follows: trimethoprim-sulfamethoxazole, 9.0%; chloramphenicol, 0.2%; tetracycline, 1.3%; and rifampin, 0.3%. Two conspicuous findings in this study were the identification of 39 strains H. influenzae that were beta-lactamase negative but ampicillin intermediate or resistant (BLNAR) and, even more surprisingly, 17 beta-lactamase-positive isolates that were resistant to amoxicillin-clavulanate (BLPACR). Strains of H. influenzae in the first group have heretofore been very uncommon; organisms in the second group have not previously been described in the literature. The percentages of all study isolates comprised of BLNAR and BLPACR organisms were 2.5 and 1.1, respectively. Overall resistance to ampicillin was thus 38.9%, and that to amoxicillin-clavulanate was 4.5%.

Full Text

The Full Text of this article is available as a PDF (204.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Pfaller M. A., Fuchs P. C., Packer R. R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother. 1994 Oct;38(10):2419–2425. doi: 10.1128/aac.38.10.2419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bell S. M., Plowman D. Mechanisms of ampicillin resistance in Haemophilus influenzae from respiratory tract. Lancet. 1980 Feb 9;1(8163):279–280. doi: 10.1016/s0140-6736(80)90778-3. [DOI] [PubMed] [Google Scholar]
  3. Black S. B., Shinefield H. R. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatr Infect Dis J. 1992 Aug;11(8):610–613. [PubMed] [Google Scholar]
  4. Clairoux N., Picard M., Brochu A., Rousseau N., Gourde P., Beauchamp D., Parr T. R., Jr, Bergeron M. G., Malouin F. Molecular basis of the non-beta-lactamase-mediated resistance to beta-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada. Antimicrob Agents Chemother. 1992 Jul;36(7):1504–1513. doi: 10.1128/aac.36.7.1504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Doern G. V., Jorgensen J. H., Thornsberry C., Preston D. A. Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn Microbiol Infect Dis. 1986 Feb;4(2):95–107. doi: 10.1016/0732-8893(86)90143-4. [DOI] [PubMed] [Google Scholar]
  6. Doern G. V., Jorgensen J. H., Thornsberry C., Preston D. A., Tubert T., Redding J. S., Maher L. A. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother. 1988 Feb;32(2):180–185. doi: 10.1128/aac.32.2.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hardy D. J., Swanson R. N., Rode R. A., Marsh K., Shipkowitz N. L., Clement J. J. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother. 1990 Jul;34(7):1407–1413. doi: 10.1128/aac.34.7.1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jorgensen J. H., Doern G. V., Maher L. A., Howell A. W., Redding J. S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990 Nov;34(11):2075–2080. doi: 10.1128/aac.34.11.2075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jorgensen J. H., Redding J. S., Maher L. A., Howell A. W. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol. 1987 Nov;25(11):2105–2113. doi: 10.1128/jcm.25.11.2105-2113.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jorgensen J. H. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin Infect Dis. 1992 May;14(5):1119–1123. doi: 10.1093/clinids/14.5.1119. [DOI] [PubMed] [Google Scholar]
  11. Juteau J. M., Levesque R. C. Sequence analysis and evolutionary perspectives of ROB-1 beta-lactamase. Antimicrob Agents Chemother. 1990 Jul;34(7):1354–1359. doi: 10.1128/aac.34.7.1354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Khan W., Ross S., Rodriguez W., Controni G., Saz A. K. Haemophilus influenzae type B resistant to ampicillin. A report of two cases. JAMA. 1974 Jul 15;229(3):298–301. [PubMed] [Google Scholar]
  13. Malouin F., Schryvers A. B., Bryan L. E. Cloning and expression of genes responsible for altered penicillin-binding proteins 3a and 3b in Haemophilus influenzae. Antimicrob Agents Chemother. 1987 Feb;31(2):286–291. doi: 10.1128/aac.31.2.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Markowitz S. M. Isolation of an ampicillin-resistant, non-beta-lactamase-producing strain of Haemophilus influenzae. Antimicrob Agents Chemother. 1980 Jan;17(1):80–83. doi: 10.1128/aac.17.1.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Medeiros A. A., Levesque R., Jacoby G. A. An animal source for the ROB-1 beta-lactamase of Haemophilus influenzae type b. Antimicrob Agents Chemother. 1986 Feb;29(2):212–215. doi: 10.1128/aac.29.2.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mendelman P. M., Chaffin D. O., Stull T. L., Rubens C. E., Mack K. D., Smith A. L. Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae. Antimicrob Agents Chemother. 1984 Aug;26(2):235–244. doi: 10.1128/aac.26.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Montgomery K., Raymundo L., Jr, Drew W. L. Chromogenic cephalosporin spot test to detect beta-lactamase in clinically significant bacteria. J Clin Microbiol. 1979 Feb;9(2):205–207. doi: 10.1128/jcm.9.2.205-207.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Parr T. R., Jr, Bryan L. E. Mechanism of resistance of an ampicillin-resistant, beta-lactamase-negative clinical isolate of Haemophilus influenzae type b to beta-lactam antibiotics. Antimicrob Agents Chemother. 1984 Jun;25(6):747–753. doi: 10.1128/aac.25.6.747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rittenhouse S. F., Miller L. A., Kaplan R. L., Mosely G. H., Poupard J. A. A survey of beta-lactamase-producing Haemophilus influenzae. An evaluation of 5750 isolates. Diagn Microbiol Infect Dis. 1995 Apr;21(4):223–225. doi: 10.1016/0732-8893(95)00028-9. [DOI] [PubMed] [Google Scholar]
  20. Rubin L. G., Medeiros A. A., Yolken R. H., Moxon E. R. Ampicillin treatment failure of apparently beta-lactamase-negative Haemophilus influenzae type b meningitis due to novel beta-lactamase. Lancet. 1981 Nov 7;2(8254):1008–1010. doi: 10.1016/s0140-6736(81)91214-9. [DOI] [PubMed] [Google Scholar]
  21. Scriver S. R., Low D. E., Simor A. E., Toye B., McGeer A., Jaeger R. Broth microdilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group. J Clin Microbiol. 1992 Sep;30(9):2284–2289. doi: 10.1128/jcm.30.9.2284-2289.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Scriver S. R., Walmsley S. L., Kau C. L., Hoban D. J., Brunton J., McGeer A., Moore T. C., Witwicki E. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Canadian Haemophilus Study Group. Antimicrob Agents Chemother. 1994 Jul;38(7):1678–1680. doi: 10.1128/aac.38.7.1678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tomeh M. O., Starr S. E., McGowan J. E., Jr, Terry P. M., Nahmias A. J. Ampicillin-resistant Haemophilus influenzae type B infection. JAMA. 1974 Jul 15;229(3):295–297. [PubMed] [Google Scholar]
  24. Tremblay L. D., L'Ecuyer J., Provencher P., Bergeron M. G. Susceptibility of Haemophilus influenzae to antimicrobial agents used in Canada. Canadian Study Group. CMAJ. 1990 Nov 1;143(9):895–901. [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES